Diabetes Drug Tirzepatide Cuts Alcohol Cravings by Over 50% in Tests

A substance originally used for diabetes could soon help individuals grappling with alcohol addiction. Research from the University of Gothenburg indicates that tirzepatide, the active component in Mounjaro, significantly reduced alcohol consumption by over half in animal tests. Scientists hypothesize it may also hinder relapses by gradually modifying the brain's reward system.

Tirzepatide operates distinctively from current addiction treatments. It targets two key receptors—GIP and GLP-1—which may provide it a stronger impact on addictive behavior than drugs like semaglutide. Studies suggest it diminishes cravings by dampening the brain's dopamine response to alcohol.

The drug's influence might not be transient. Early findings hint at long-term biological alterations, including epigenetic modifications that could permanently reshape addictive patterns. Despite these encouraging results, no human trials have yet been submitted to regulatory bodies like the EMA or FDA.

Because tirzepatide is already approved for diabetes, the route to approval for alcohol dependence could accelerate. However, more human studies are required before it can be prescribed for this new purpose.

If approved, tirzepatide would provide a novel approach to treating alcohol addiction. It could become the first medication to address both cravings and relapse risk through enduring brain changes. For now, researchers are preparing the next steps to transition it from animal labs to clinical practice.